Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer — Stella

Home/Epithelial Ovarian Cancer/NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

View on ClinicalTrials.gov

Recruiting

Back to Epithelial Ovarian Cancer trials

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Netherlands

Radboud University Medical Center, Nijmegen, Gelderland

Key details

Phase

Early testing / Safety & dosing

Sponsor

Radboud University Medical Center

Enrollment target

~10 participants

Started

March 2023

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Sex

Female only

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.